Expected proceeds from the July public offering was over $15 million. Exec salaries are low compared to industry standards, which means they are not throwing money away that easily. I think a paternship is vital to get any of these drugs successfully marketed, which is just as important as getting FDA approval. This should be the next milestone and once it happes the marketing can begin to lead to revenue. Optimistic I am, but we shall see.
just raised $17 million, should be enough until they partner up the premature ejack drug. Not sure what others think but it seems several big pharma companies would be greatly interested in marketing this drug. The TV commercials should be quite interesting.
Of course they could buy the whole company because that inflammatory drug alone justifies todays market cap. New shareholder as of this morning and I'm damn glad to be here. Very happy this didn't get away from me because I should have bought this after the cash raise and forgot about it.